Drug interactions between opioids and antiretroviral medications: Interaction between methadone, LAAM, and nelfinavir

被引:37
作者
McCance-Katz, EF
Rainey, PM
Smith, P
Morse, G
Friedland, G
Gourevitch, M
Jatlow, P
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Buffalo, Adult ACTG Pharmacol Support Lab, Buffalo, NY USA
[4] Yale Univ, Sch Med, New Haven, CT USA
[5] NYU, New York, NY USA
关键词
D O I
10.1080/10550490490436037
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Understanding drug interactions between antiretrovirals and opiate therapies may decrease toxicities and enhance adherence, with improved HIV outcomes in injection drug users. We report results of a clinical pharmacology study designed to examine the interaction of the protease inhibitor, nelfinavir, with methadone and LAAM ( N = 48). Nelfinavir decreased methadone exposure, but no withdrawal was observed over the five day study period. LAAM and dinorLAAM concentrations were decreased, while norLAAM concentrations were increased, with minimal overall change in LAAM/metabolite exposure. Methadone and LAAM did not affect nelfinavir concentrations, but methadone decreased M8 metabolite exposure. While no toxicities were observed, clinicians should be aware of the potential for drug interactions when patients require treatment with nelfinavir and these opiate medications.
引用
收藏
页码:163 / 180
页数:18
相关论文
共 46 条
[1]   METHADONE PLASMA-PROTEIN BINDING - ALTERATIONS IN CANCER AND DISPLACEMENT FROM ALPHA-ACID GLYCOPROTEIN [J].
ABRAMSON, FP .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (05) :652-658
[2]   Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone [J].
Altice, FL ;
Friedland, GH ;
Cooney, EL .
AIDS, 1999, 13 (08) :957-962
[3]  
American Psychiatric Association, 2000, Text revision (DSM-IV-TR), V4th, DOI [10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr, DOI 10.1176/DSM10.1176/APPI.BOOKS.9780890420249.DSM-IV-TR]
[4]  
[Anonymous], EMEA877601
[5]   Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients [J].
Baede-van Dijk, PA ;
Hugen, PWH ;
Verweij-van Wissen, CPWGM ;
Koopmans, PP ;
Burger, DM ;
Hekster, YA .
AIDS, 2001, 15 (08) :991-998
[6]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[7]   Nelfinavir - An update on its use in HIV infection [J].
Bardsley-Elliot, A ;
Plosker, GL .
DRUGS, 2000, 59 (03) :581-620
[8]  
Beauverie P, 1998, AIDS, V12, P2510
[9]  
Borenstein M., 1988, STAT POWER ANAL
[10]  
CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059